AFP and hepatocellular carcinoma: As shown in Figure 2b, the cumulative incidence of HCC-R in patients was significantly lower than in patients with an AFP >8 (3-year incidence: 52.7% with AFP ≤ 8 and 76.3% with AFP > 8, p = 0.0327, log-rank test) and palliative treatment (3-year incidence: 52.5% without TACE and 92.8% with TACE, p < 0.001, log-rank test).